Spread the Word

09-photo-1

Every Registry member brings us one step closer to our goal of ending Alzheimer's.

The Registry has a single purpose: accelerating research by connecting researchers with people like you who are interested in taking part in Alzheimer's-focused studies.

If you're on social media, show your friends and family that you've joined the fight against Alzheimer's. Share the Facebook and Twitter posts below.

Invite your family and friends

It's as easy as sending a quick email. Each person who joins the Registry will play a significant role in the fight against this devastating disease.

Spread the word on Facebook

Click here to share on Facebook

Spread the word on Twitter

Click here to share on Twitter

Show Your Support

Spreading the word can be as easy as one click:

Recent News
older active friends_cropped
A decline in dementia could be linked to healthier arteries
Recent articles have reported a possible decline in dementia. What is causing it? Researchers examined data from more than 1500 brain autopsies to find out. The results could help scientists better understand the link between Alzheimer’s disease and cardiovascular health.
Read More
Happy senior man cropped
Rare gene mutation delays onset of early Alzheimer’s by 30 years

A brother and sister in Medellin, Colombia benefitted from a rare gene mutation that protected them from developing the early onset Alzheimer’s disease that is rampant in their extended family. How did this gene stave off symptoms for so long? And how is it related to the case of a distant relative, discovered four years ago, whose cognitive decline was delayed 30 years by a different gene mutation? 

Read More
MRI Image scan review shutterstock_cropped
Almost half of participants in anti-amyloid study show no disease progression in one year
Eli Lilly recently announced positive results for their Trailblazer-ALZ 2 Phase 3 clinical trial. The drug donanemab slowed cognitive and functional decline in a significant portion of study participants diagnosed with early-stage Alzheimer’s disease. This is the third drug reported to show a link between amyloid plaque clearance and lessening the progression of disease symptoms.
Read More